Regencell Bioscience Holdings Limited
HKFinancials
Valuation Metrics
Regencell Bioscience Holdings Limited's Market Cap is $2.86B. At end of 2025 it was $10.38B. Ranked #1755 of 3,121 in US market (top 56%), #630 of 1,463 on NASDAQ (top 43%), #106 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 40%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.86B | US#1,755/3,121 Sec#106/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-4M | US—/3,121 Sec—/266 |
| Total Assets | $6M | US#3,098/3,121 Sec#268/266 |
| Net Assets | $5M | US#2,921/3,121 Sec#242/266 |
| Employees | 10 | US#2,786/3,121 Sec#224/266 |
| Value | ||
| P/B | 589.08x | US#2,921/3,121 Sec#242/266 |
| FCF Yield | -0.11% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -73.75% | US#2,761/3,121 Sec#191/266 |
| ROA | -62.27% | US#3,021/3,121 Sec#230/266 |
| Financial Health | ||
| Debt Ratio | 18.42% | US#209/3,121 Sec#75/266 |
| Total Debt | $544415.00 | US#3,000/3,121 Sec#253/266 |
| FCF | $-3M | US#2,341/3,121 Sec#88/266 |
| Cash | $2M | US#3,052/3,121 Sec#266/266 |
| Current Ratio | 7.39x | US#340/3,121 Sec#106/266 |
| Performance | ||
| 1Y Return | -61.78% | US#3,024/3,121 Sec#251/266 |
| 1M Return | -0.34% | US#268/3,121 Sec#31/266 |
| From 52W High | -91.61% | US#3,119/3,121 Sec#266/266 |
| 1Y MDD | -90.96% | US#3,117/3,121 Sec#264/266 |
| Trading | ||
| Volume | 86,415 shares | US#2,995/3,121 Sec#262/266 |
| Trading Value | $508984.00 | US#3,079/3,121 Sec#262/266 |
| Per Share | ||
| EPS | $-0.01 | US—/3,121 Sec—/266 |
| BPS | $0.01 | US#2,811/3,121 Sec#238/266 |
Company Info
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.